NEWS
Genomics England to play key role supporting 10 Year Health Plan
Genomics England will help deliver the 10 Year Health Plan through its digital systems and by generating the evidence to inform how genomics could be embedded into routine care – shaping future approaches to earlier diagnosis, prevention and more personalised treatment. Supported by the 10 Year Health Plan, Genomics England will complete the Generation Study, a research study in partnership with the NHS, that is sequencing the genomes of 100,000 newborns with parental consent. The study aims to improve how we diagnose and treat rare conditions and will evaluate the use of genome sequencing to identify more than 200 rare genetic conditions that appear in the first few years of life, can be improved if caught early and treated in the NHS. Insights from the Generation Study will inform the Government’s longer-term ambition to offer genomic sequencing at birth in the future. By delivering research programmes that build the evidence and digital infrastructure to support wider adoption of genomics in healthcare, Genomics England will help position the UK as the leader in genomics- enabled prevention and diagnostics. Genomics England’s continued work to deliver digital systems that support the
NHS and connect routine care to research via the National Genomic Research Library, will enable clinicians and researchers to fully harness the power of genomics. By 2030, the National Genomic Research Library – which is already one of the world’s largest databases of its kind – will house over 500,000 whole genomes from the 100,000 Genomes Project, the NHS Genomic Medicine Service, the Generation Study and other research programmes. The growth of the National Genomic Research Library will benefit NHS patients and participants by uncovering new diagnoses and driving the development of innovative treatments. Dr Rich Scott, Chief Executive Officer of Genomics England, commented: “Genomics is already playing an important role in healthcare and has the potential to increase its impact dramatically, becoming part of everyday healthcare help drive more efficient and predictive care that leads to better health for all. The UK has long been a global leader in genomics. This continued support will strengthen our ability to harness the full potential of genomics and data- driven healthcare that will benefit the public for generations to come.”
New collaboration for AI cancer diagnostics
Lunit, a provider of AI for cancer diagnostics and therapeutics, has announced a new collaboration with Microsoft to accelerate the delivery of AI- powered healthcare solutions. In conjunction with Lunit’s recent acquisition of Volpara, a Microsoft Industry Health Certified Partner, this collaboration will give health professionals globally access to tools that will assist in the detection of cancer. This underscores Lunit’s long-term vision to move beyond standalone AI tools – toward building integrated solutions that align with real-world clinical practice. By joining forces with Microsoft, Lunit is poised to deliver scalable technologies that not only streamline workflows but also drive measurable improvements in diagnostic
consistency and patient care across diverse healthcare settings.
This marks a significant milestone in
Lunit’s mission to expand access to AI tools, particularly in the US market, by leveraging Microsoft Azure’s global cloud infrastructure and deep expertise in healthcare-focused AI technologies.
“For AI to truly make an impact in
healthcare, it must be accessible, scalable, and seamlessly integrated into clinical practice,” said Brandon Suh, CEO of Lunit. “Our collaboration with Microsoft enables us to bring our AI to more providers through trusted platforms like Microsoft Azure, helping us expand access in the U.S. and beyond. This collaboration brings us one step closer to delivering high-quality, consistent care through AI, at scale.”
WWW.PATHOLOGYINPRACTICE.COM AUGUST 2025 9
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72
